Searched for: +
(1 - 3 of 3)
document
Nieuwenhuizen, W. (author), Voskuilen, M. (author), Hermans, J. (author), Gaubius instituut TNO (author)
The present study was undertaken as a step to delineate further the localization of the calcium-binding sites in fibrinogen and to assess the anticlotting properties of fibrinogen degradation products. To this purpose, fragments Y were prepared by plasmin digestion of human fibrinogen in the presence of added Ca2+, and purified. We found that,...
article 1982
document
Gaubius Instituut TNO (author), Rijken, D.C. (author), Groeneveld, E. (author), Kluft, C. (author), Nieuwenhuis, H.K. (author)
α2-Antiplasmin Enschede is a variant of α2-antiplasmin which has lost its ability to inhibit plasmin irreversibly and which is associated with haemorrhagic disorder [Kluft et al. (1987) J. Clin. Invest. 80, 1391-1400]. The abnormal protein was purified from the plasma of a homozygous patient and subjected to one-dimensional peptide mapping using...
article 1988
document
Rijken, D.C. (author), Barrett-Bergshoeff, M.M. (author), Jie, A.F.H. (author), Criscuoli, M. (author), Sakharov, D.V. (author), Gaubius Instituut TNO (author)
Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...
article 2004